Trials / Completed
CompletedNCT02317198
Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,011 (actual)
- Sponsor
- St. Antonius Hospital · Academic / Other
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
A randomized controlled, open label, multicenter trial with 1000 patients aged 70 years and older, presenting with Non-ST-elevation acute coronary syndrome. Patients will be randomized to either clopidogrel or the novel P2Y12 inhibitor (ticagrelor or prasugrel). Patients will be followed for one year for outcomes such as bleeding episode requiring medical intervention and net clinical benefit (all cause mortality, non-fatal myocardial infarction, non-fatal stroke, PLATO major and minor bleeding).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clopidogrel | |
| DRUG | Ticagrelor or Prasugrel |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2018-11-01
- Completion
- 2019-11-01
- First posted
- 2014-12-15
- Last updated
- 2024-05-30
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02317198. Inclusion in this directory is not an endorsement.